Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

INTRODUCTION: In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI). METHOD: The data of 16 laboratory-confirmed COVID-19 patients with CML receiving TKI and age, gender, and comorbid disease matched COVID-19 pati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Oncol Pharm Pract
Hlavní autoři: Başcı, Semih, Ata, Naim, Altuntaş, Fevzi, Yiğenoğlu, Tuğçe Nur, Dal, Mehmet Sinan, Korkmaz, Serdal, Namdaroğlu, Sinem, Baştürk, Abdülkadir, Hacıbekiroğlu, Tuba, Doğu, Mehmet Hilmi, Berber, İlhami, Dal, Kürşat, Erkurt, Mehmet Ali, Turgut, Burhan, Çağlayan, Murat, Ayvalı, Mustafa Okan, Çelik, Osman, Ülgü, Mustafa Mahir, Birinci, Şuayip
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7506180/
https://ncbi.nlm.nih.gov/pubmed/32854573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1078155220953198
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky